| Literature DB >> 14585555 |
Eduardo Bruera1, Florian Strasser, Loren Shen, J Lynn Palmer, Jie Willey, Larry C Driver, Allen W Burton.
Abstract
Opioid-induced sedation is a major complication in patients with cancer pain. This study assessed the effectiveness of donepezil in opioid-induced sedation and related symptoms in patients with cancer pain. Twenty-seven patients who were receiving strong opioids for pain and reported sedation were enrolled. Donepezil 5 mg was given every morning for 7 days. Changes between baseline and Day 7 in sedation, pain, fatigue and other symptoms were evaluated using the Edmonton Symptom Assessment Scale. Fatigue was also measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue). Overall usefulness of donepezil was measured by the patient at the end of the study. In 20 evaluable patients, sedation, fatigue, anxiety, well-being, depression, anorexia and problems with sleep were significantly improved. Side effects included nausea, vomiting, diarrhea, muscle and abdominal cramps, and anorexia. Overall, however, the treatment was well tolerated. Donepezil appears to improve sedation and fatigue in patients receiving opioids for cancer pain. Randomized controlled trials of this agent are justified.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14585555 DOI： 10.1016/s0885-3924(03)00332-4
Source DB: PubMed Journal: J Pain Symptom Manage ISSN： 0885-3924 Impact factor: 3.612